<?xml version="1.0" encoding="UTF-8"?>
<p>RNA tests can confirm the diagnosis of SARS-CoV-2 (COVID-19) cases with real-time RT-PCR or next-generation sequencing (
 <xref rid="B148" ref-type="bibr">148</xref>, 
 <xref rid="B149" ref-type="bibr">149</xref>, 
 <xref rid="B245" ref-type="bibr">245</xref>, 
 <xref rid="B246" ref-type="bibr">246</xref>). At present, nucleic acid detection techniques, like RT-PCR, are considered an effective method for confirming the diagnosis in clinical cases of COVID-19 (
 <xref rid="B148" ref-type="bibr">148</xref>). Several companies across the world are currently focusing on developing and marketing SARS-CoV-2-specific nucleic acid detection kits. Multiple laboratories are also developing their own in-house RT-PCR. One of them is the SARS-CoV-2 nucleic acid detection kit produced by Shuoshi Biotechnology (double fluorescence PCR method) (
 <xref rid="B150" ref-type="bibr">150</xref>). Up to 30 March 2020, the U.S. Food and Drug Administration (FDA) had granted 22 
 <italic>in vitro</italic> diagnostics Emergency Use Authorizations (EUAs), including for the RT-PCR diagnostic panel for the universal detection of SARS-like betacoronaviruses and specific detection of SARS-CoV-2, developed by the U.S. CDC (
 <xref rid="T1" ref-type="table">Table 1</xref>) (
 <xref rid="B258" ref-type="bibr">258</xref>, 
 <xref rid="B259" ref-type="bibr">259</xref>).
</p>
